Physician profile
Nelson E Aguilar
NPI 1760687842
$3,856.18
in general payments reported to CMS, 2019-2025
23 companies · $879 in 2025
The $879 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $202 · 2021: $552 · 2022: $645 · 2023: $627 · 2024: $769 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,275.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $586.68 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $485.59 | 2019-2025 | Eliquis, Camzyos |
| Pfizer INC. | $408.34 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $332.51 | 2021-2025 | |
| Abbott Laboratories | $281.94 | 2021-2025 | Aveir, Gallant |
| Novartis Pharmaceuticals Corporation | $247.52 | 2019-2024 | |
| Cvrx, INC. | $212.18 | 2023-2025 | Barostim Neo System |
| Boston Scientific Corporation | $211.13 | 2022-2025 | Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $202.01 | 2021-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $190.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $182.73 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $164.86 | 2021-2024 | Ozempic, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.86 | 2019-2024 | Lifevest |
| Biotronik INC. | $49.67 | 2021-2023 | Biomonitor |
| Medtronic Vascular, INC. | $46.82 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $35.08 | 2025 | Onpattro |
| Vital Connect, INC | $31.43 | 2024 | Vitalpatch Rtm |
| Edwards Lifesciences Corporation | $22.66 | 2025 | |
| Medicomp INC | $19.97 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $19.48 | 2023 | Inpefa |
| Cmp Pharma, INC. | $16.28 | 2023 | Carospir, Tadliq |
| Vifor Pharma, INC. | $15.60 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nelson Aguilar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.